Stroke is the second leading global cause of death and a leading cause of disability, according to the World Health Organization. When a blood vessel in the brain is blocked by a clot, an ischemic stroke occurs, preventing blood flow.
Galway-based Perfuze is a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke by providing safe, cost-effective therapy. The startup has just closed a €3 million seed investment round, which it will use to further develop its Millipede platform technology.
The funding was led by Earlybird, one of Europe’s largest venture capital firms, investing from its Health Tech Fund, joined by MedFocus, investing from its HBM-MedFocus Fund, and Enterprise Ireland.
“Perfuze has a technology with the potential to significantly improve outcomes for stroke patients,” says John Yianni, Partner at Earlybird. “We are delighted to offer our financial and commercial support in helping this exciting company grow and get its life-saving technology to market.”
The Irish company was founded in 2018 by Wayne Allen and Liam Mullins, who have over 30 years combined medtech experience within startups and large corporations.
“We are delighted to have completed our seed round financing with such reputable investors and look forward to working together to accelerate the growth and value of Perfuze,” said Wayne Allen, CEO of Perfuze.
